Findings support a role for teleneurology in MS management
Phase 2 clinical study supports safety and efficacy of MSC-NTFs
Database study reveals racial differences across clinical and imaging domains
Shortcomings in specificity show influence of cortical changes beyond demyelination
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A new NAIMS consensus statement summarizes evidence, guides MRI investigation
Ambulation disability carries greatest risk, most disease-modifying therapies aren’t implicated
Clinical cohort study helps define red flags for these rare MS mimics
Survey suggests need for education about FDA’s mission, trustworthiness
Large cohort study supports early consideration of aggressive therapy
Cannabinoid oromucosal spray is poised for FDA submission in 2021
Advertisement
Advertisement